Is Hims & Hers Stock in Trouble?
Hims & Hers Health (HIMS 6.30%) is coming off a fantastic year in 2024 when its share price skyrocketed 172%. The telehealth company has been growing at a fast rate, making it one of the best stocks to own in healthcare of late.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $25.90, moving +1.93% from the previous trading session.
Hims & Hers Stock Is Poised for a Major Surge in 2025
Hims & Hers (HIMS -4.02%) has been on a wild journey over the past year as GLP-1s drive both big gains and big losses for the stock. But the business is about much more than just one product, and Travis Hoium explains why investors should expect an expanded platform in 2025.
Don't Buy Hims & Hers Stock If You Want Better Than Mediocre Returns
Hims & Hers capitalizes on telehealth growth in hair, mental, sexual health, and weight loss. Yet, limited product differentiation, reliance on branding, and FDA risks weaken its long-term moat. Forecasting $3.79B in revenue and $1.08 EPS by 2030, a $45.90 midpoint price target implies an 11.5% five-year CAGR, underperforming a 15% return expectation for a Buy rating. Despite strong branding and subscription revenue, slim competitive advantages and valuation concerns justify a Hold rating, emphasizing risks from generic pricing and market competition.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Zacks.com users have recently been watching Hims & Hers Health (HIMS) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Hims & Hers Health, Inc. (HIMS) Laps the Stock Market: Here's Why
Hims & Hers Health, Inc. (HIMS) closed the most recent trading day at $26.90, moving +1.01% from the previous trading session.
Hims & Hers: Ready For Liftoff In 2025
Despite a recent 30% stock drawdown, Hims & Hers Health, Inc. remains a “Strong Buy” due to its undervaluation and long-term growth potential in the healthcare tech market. Hims & Hers' robust Q3 2024 performance, driven by a 44% increase in subscribers and 77% y/y revenue growth, underscores its strong growth trajectory. Management's raised FY-2024 revenue outlook and strategic initiatives, including new weight loss offerings and personalization, bolster confidence in sustained growth.
Is Hims & Hers Health a Millionaire Maker?
Hot telehealth stock Hims & Hers Health (HIMS -3.93%) has been a roller coaster in 2024. After a recent decline, the stock is down more than 25% from its high.
3 Hot Stocks That Can Double Again in 2025
Some of the hottest stocks of 2024 may surprise you. A few more than 100 stocks with market caps north of $2 billion doubled over the past year.
Hims & Hers Health, Inc. (HIMS) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Hims & Hers Health (HIMS). This makes it worthwhile to examine what the stock has in store.
Hims & Hers: Still Trading At A Massive Discount
Hims & Hers Health is revolutionizing telehealth with a vertically integrated model, offering personalized medications and achieving rapid subscription growth, driving long-term profitability and differentiation. HIMS' financials are robust, with 40% annual subscription growth and a forecasted 60%+ revenue growth for 2024, indicating significant undervaluation despite a 200% YTD increase. The company is expanding its product offerings and leveraging AI through MedMatch, enhancing treatment consistency and customer satisfaction, further solidifying its market position.
Will the falling Hims & Hers stock price recover in 2025?
Hims & Hers stock price has greatly performed this year as it continued to disrupt the healthcare industry. HIMS has jumped by almost 200% this year, while other companies in the industry like CVS Health and Walgreens Boots Alliance and CVS Health, plunged.
